These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29451049)

  • 21. Clodronic acid in the treatment of postmenopausal osteoporosis.
    Tanakol R; Yarman S; Bayraktaroglu T; Boztepe H; Alagöl F
    Clin Drug Investig; 2007; 27(6):419-33. PubMed ID: 17506592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intramuscular neridronate in postmenopausal women with low bone mineral density.
    Adami S; Gatti D; Bertoldo F; Sartori L; Di Munno O; Filipponi P; Marcocci C; Frediani B; Palummeri E; Fiore CE; Costi D; Rossini M
    Calcif Tissue Int; 2008 Nov; 83(5):301-7. PubMed ID: 18946626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin D and bone mineral density changes in postmenopausal women treated with strontium ranelate.
    Catalano A; Morabito N; Di Stefano A; Morini E; Basile G; Faraci B; Loddo S; Ientile R; Lasco A
    J Endocrinol Invest; 2015 Aug; 38(8):859-63. PubMed ID: 25952299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting.
    Roberts J; Castro C; Moore AE; Fogelman I; Hampson G
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):509-15. PubMed ID: 26715263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
    Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H; Taguchi A
    Osteoporos Int; 2017 Feb; 28(2):559-566. PubMed ID: 27650642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
    Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
    Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy.
    Hochberg MC; Silverman SL; Barr CE; Miller PD
    J Clin Densitom; 2010; 13(2):181-9. PubMed ID: 20347369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Suzuki T; Nakamura Y; Tanaka M; Kamimura M; Ikegami S; Uchiyama S; Kato H
    Mod Rheumatol; 2018 Mar; 28(2):376-379. PubMed ID: 28397581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
    Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.
    Cairoli E; Palmieri S; Goggi G; Roggero L; Arosio M; Chiodini I; Eller-Vainicher C
    J Endocrinol Invest; 2018 Aug; 41(8):1005-1013. PubMed ID: 29340971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.
    Middleton ET; Steel SA; Aye M; Doherty SM
    J Bone Miner Res; 2010 Mar; 25(3):455-62. PubMed ID: 20201000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
    Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
    Calcif Tissue Int; 2017 Oct; 101(4):396-403. PubMed ID: 28589205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
    Guan YT; Cai LL; Ding HX; Chen GD; Hu Y
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):571-4. PubMed ID: 21029610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fracture during oral bisphosphonate therapy is associated with deteriorated bone material strength index.
    Nogués X; Prieto-Alhambra D; Güerri-Fernández R; Garcia-Giralt N; Rodriguez-Morera J; Cos L; Mellibovsky L; Pérez AD
    Bone; 2017 Oct; 103():64-69. PubMed ID: 28655603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QCT bone mineral density responses to 1 year of oral bisphosphonate after total knee replacement for knee osteoarthritis.
    Lee JK; Lee CH; Choi CH
    Osteoporos Int; 2013 Jan; 24(1):287-92. PubMed ID: 22358316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
    Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.